A Uniquely Scalable Approach to Sequence Tens of Millions of Single Cells Without Compromising Performance

免疫疗法（包括CAR-T细胞疗法）在起作用时是神奇的药物，但 当今免疫疗法的反应率仅为15-20%， 高得让人望而却步单细胞测序的最新进展使其成为关键的 通过高影响力应用开发下一代细胞疗法的工具， 作为TCR免疫分析和合并的CRISPR筛选。释放这些价值 应用要求每次实验询问> 1000万个细胞。Illumina的核心 2023年的知识产权重新点燃了美国和欧盟市场的竞争，并重新加速了DNA的下降 在1-2年内使~ 1000万个细胞的测序负担得起的测序成本，但现有的 用于单细胞条形码化的方法不支持每个实验超过1百万个细胞的通量。 建议的替代方案是可扩展的，但性能和易用性的权衡使它们 不适合翻译研究。Sansimeon的方法独特地使规模化的单细胞 测序通量可达1亿个细胞，同时保留高易用性和必要的细胞 转化研究中高通量应用的捕获效率。平台 克服了其他drop-seq方法常见的通量限制， 乳化前微通道中单细胞与单珠的确定性配对， 而不需要多步骤标记工作流程，例如单元散列或组合索引。

Immunotherapies (including CAR-T cell therapies) are wonder drugs when they work, but the response rates of today’s immunotherapies are only 15-20% and therapy costs remain prohibitively high for mass adoption. Recent advances in single cell sequencing make it a critical tool for the development of next generation cell therapies through high impact applications such as TCR immune profiling and pooled CRISPR screening. Unlocking the value of these applications requires interrogation of >10 million cells per experiment. Expiration of Illumina’s core IP in 2023 re-ignited competition in US & EU markets and re-accelerated the drop in DNA sequencing costs to make sequencing of ~10 million cells affordable in 1-2 years, but existing methods for single cell barcoding do not support throughput beyond 1 million cells per experiment. Proposed alternatives are scalable, but trade-offs in performance and ease-of-use make them unsuitable for translational research. Sansimeon’s approach uniquely enables scaled single cell sequencing with throughput to 100M cells, while retaining high ease-of-use and necessary cell capture efficiency for high-throughput applications in translational research. The platform overcomes throughput limitations common to other drop-seq approaches by leveraging rapid deterministic pairing of single cells with single beads in a microchannel prior to emulsification, without the need for multi-step labeling workflows such as cell-hashing or combinatorial indexing.